Navigation Links
Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
Date:1/7/2008

SAN DIEGO, Jan. 7 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents, announced today that it has started testing its lead product, Hemospan(R), in a Phase II clinical study involving chronic critical limb ischemia (CCLI) patients.

The single-blind, placebo-controlled study at the Karolinska Institute in Stockholm, Sweden is designed to evaluate the safety and efficacy of Hemospan in patients suffering from CCLI, a debilitating condition that results from severely limited blood circulation to the legs. The primary endpoint is tissue oxygenation measured noninvasively.

The goal of this study is to demonstrate that Hemospan can increase oxygen supply to severely compromised tissue, conclusively establishing it as an 'oxygen-carrying plasma expander,'" said Dr. Robert Winslow, Chairman, President and CEO of Sangart.

Hemospan is a hemoglobin-based oxygen transport agent designed to serve as an oxygen therapeutic and as an alternative to blood transfusions. A key property of Hemospan is its high oxygen affinity which results in targeted oxygen delivery to tissues at risk of oxygen deprivation.

About Sangart

Sangart is a privately held biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as oxygen transport agents.

Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-free hemoglobin solutions, funded by competitive grants from the National Institutes of Health and the Department of Defense. The counterintuitive discoveries by Dr. Winslow's group on the effective action of oxygen transport agents have been patented and published in numerous scientific articles. Fro
'/>"/>

SOURCE Sangart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
2. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
3. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
4. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
5. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
6. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
7. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
10. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
11. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...nking polyphenol-rich 100% Concord grape,juice was...ntake or body,weight, CONCORD, Mass., Oct. 6 /PRN...-rich Concord grape juice did not cause significan...appetite and was shown to reduce waist,circumferen...ual Meeting of,the American College of Nutrition i...
(Date:10/3/2008)...ase Inhibitors for Cancer Treatments, INDIANAPOLI...stCall/ --,Eli Lilly and Company (NYSE: LLY ) and...ay announced that the two companies have entered,i...ent related to,Deciphera,s preclinical B-Raf kinas...ology therapeutics., The collaboration will apply...
(Date:10/2/2008)...RNewswire/ -- Calabar AB announced today,that thei... mouth"),patients has been initiated. Specifically...s between the ages of 20 to 75. The objective of t...ucceeding Phase III efficacy,study., Xalieve(TM) ...hysostigmine. It is administered locally in the mo...
(Date:10/1/2008)...tial of Amylin,s integrated neurohormonal ... DIEGO, Oct. 1 /- Amylin Ph...ed that new data for its pipeline obesity,candidat... Meeting of The,Obesity Society in Phoenix October...of the largest and most comprehensive scientific c...
Breaking Medicine Technology:Concord Grape Juice Has No Significant Impact on Body Weight 2Concord Grape Juice Has No Significant Impact on Body Weight 3Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 2Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 3Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Docs Issue Guideline on Screening for Osteoporosis in Men 18604 1Docs Issue Guideline on Screening for Osteoporosis in Men 18604 2iCAD Reports First Quarter 2008 Financial Results 5164 1iCAD Reports First Quarter 2008 Financial Results 5164 2iCAD Reports First Quarter 2008 Financial Results 5164 3iCAD Reports First Quarter 2008 Financial Results 5164 4iCAD Reports First Quarter 2008 Financial Results 5164 5iCAD Reports First Quarter 2008 Financial Results 5164 6iCAD Reports First Quarter 2008 Financial Results 5164 7iCAD Reports First Quarter 2008 Financial Results 5164 8iCAD Reports First Quarter 2008 Financial Results 5164 9Pharm Olam Finds VoIP Solution in Taridium LLC 5160 1Pharm Olam Finds VoIP Solution in Taridium LLC 5160 2Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 1Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 2Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 3Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 4Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 5Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 6Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 7Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 8Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 9
...ING, N.J.--(BUSINESS WIRE)--Apr 19, 2007 - Antares...ts from a recently completed,site application stud...TD(TM) transdermal gel, was absorbed on a bioequiv...ee different skin site,locations., The study was a...lication site pharmacokinetic study. The trial enr...
...Unique Viral Kinetics Profile, LAUSANNE, Switzerla...p (Debiopharm), a global independent biopharmaceut...s medical conditions,presented additional results...ilin (Cyp) inhibitor Debio 025 in HIV/HCV (hepatit...esented at the 42nd,Annual Meeting of the European...
Other Medicine Technology:Antares Pharma Announces Positive Results from Application Site,Study for Anturol 2Antares Pharma Announces Positive Results from Application Site,Study for Anturol 3Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 2Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 3Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 4
(Date:10/6/2008)...childhood obesity, researcher notes , ,...s of middle schools have vending machines where sn...s. , The research demonstrates that there are v...those vending machines don,t always have the healt...istered dietitian with the Center for Obesity Rese...
(Date:10/6/2008)...Call/ -- HealthSouth,Corporation (NYSE: HLS ) tod...zed investor meeting in New York City. Presentatio...T at the Grand Hyatt New York, located at,109 E. 4..., 8:00 a.m. Continental Breakfast 8:30 a.m. ...r -- HealthSouth Overview and Industr...
(Date:10/6/2008)...eir family members can take,anonymous online, tele... 6 /PRNewswire-USNewswire/ -- Military life can pr...lies that are unique and,difficult. Some are manag...,worse and one problem can trigger other more seri...gs out to see what is really happening., (Photo: ...
(Date:10/6/2008)... of California, San Diego School of Medicine sugge...s production of a protective chemical normally fou...ns that are a common result of atopic dermatitis, ... by Richard Gallo, M.D., Ph.D., professor of medic...e UCSD School of Medicine and the Dermatology sect...
Breaking Medicine News(10 mins):Health News:Vending Machines Found in Most Middle Schools 2Health News:HealthSouth to Hold Investor Meeting November 10, 2008 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 3Health News:Oral vitamin D may help prevent some skin infections 2
...c'? No, its not another eating disorder, it's just...Professor Bruce Davies, of the University of Glamo... same problems as faced by people suffering from a...ncreasingly resorting to steroids and prescription...
...the Bombay High Court today raised the issue of sp...irected to take steps to curb the trade of such dr...ernment to file a reply in this regard by July 12....at Raj Mehta, who lost his son due to administrati...
...udents in New Zealand report low levels of perceiv...as a result, according to a new survey//. The Yout...Regional Public Health Service and Auckland Univer...nts about their mental and physical health, beside...
...ic surgery, most people want reduction of fat in a...hich involves a procedure wherein the body fat is ...uction is one of the most popular cosmetic surgery...nique are used to liquefy the fat and suck it out....
Other Medicine News:Health News:Indian Students in New Zealand Feel Insecure 2
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
Medicine Products: